---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-225853"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:02:57.895388+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme to acquire Elektrofi for $750M upfront, expanding drug delivery offerings into 2040s

## Summary
- Upfront payment $750M; up to three $50M milestones contingent on product regulatory approvals.
- Hypercon technology enables 400-500 mg/ml concentrations, up to 4-5x standard aqueous formulations.
- Two partner products expected to begin clinical development by year-end 2026 or earlier.
- Royalty revenue expected to begin 2030; deal less than 5% dilutive to Non-GAAP EPS over medium term.
- Halozyme reaffirms 2025 guidance: rev $1.275-1.355B, Adj EBITDA $865-915M, Non-GAAP EPS $6.00-6.40.

## SEC filing metadata
- accession: 0001193125-25-225853
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312525225853/0001193125-25-225853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312525225853/d940775d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-225853
- JSON: https://secwatch.observer/filing/0001193125-25-225853.json
- Plain text: https://secwatch.observer/filing/0001193125-25-225853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.